LOGO.jpg
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
17 févr. 2022 08h30 HE | Celsion Corporation
OVATION 2 Study is Over 75% Enrolled; Full Enrollment Expected by Mid-2022 Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over...
Logo.png
Advanced Ovarian Cancer Pipeline Report: Current Therapies, Emerging Drugs, and Treatment Outlook | DelveInsight
20 sept. 2021 20h00 HE | DelveInsight Business Research LLP
Los Angeles, USA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Advanced Ovarian Cancer Pipeline Report: Current Therapies, Emerging Drugs, and Treatment Outlook | DelveInsight There are approximately 50+ key...
Logo.jpg
Results of Celsion’s OVATION 1 Study with GEN-1 in Patients with Advanced Ovarian Cancer Published in the Journal of Clinical Cancer Research
29 juil. 2021 10h00 HE | Celsion CORP
Data show dose-dependent suppression of immune-suppressive agents GEN-1 stimulates the immune system through the production of CD4 and CD8 cells Chemotherapy Response...
Logo.jpg
Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer
22 févr. 2021 07h30 HE | Celsion CORP
Celsion’s Commitment to Promoting Immune System Solutions to Fight Life-Threatening Diseases Granted an Accelerated Development Pathway Designation Provides Potential for an Expedited...
Logo.jpg
Celsion Corporation Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer
27 juil. 2020 08h30 HE | Celsion CORP
Promising Translational and Clinical Findings Support the Randomized Trial in Newly Diagnosed Patients Non-Viral Nanoparticle Delivery System, TheraPlas Platform, Demonstrates Potential for...
Logo.jpg
Celsion Announces Highly Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian Cancer
19 mars 2020 08h00 HE | Celsion CORP
 R0 (Complete) Surgical Resection Rates for Patients Randomized to GEN-1 Treatment Arm Compare Favorably to Patients Receiving Neoadjuvant Chemotherapy Only Company to Proceed with Phase II...